Compare VIR & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | CSTL |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.0M | 1.1B |
| IPO Year | 2019 | 2019 |
| Metric | VIR | CSTL |
|---|---|---|
| Price | $6.14 | $40.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | $25.73 | ★ $43.17 |
| AVG Volume (30 Days) | ★ 1.8M | 365.3K |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $16,860,000.00 | ★ $343,530,000.00 |
| Revenue This Year | N/A | $1.69 |
| Revenue Next Year | $46.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.15 |
| 52 Week Low | $4.16 | $14.59 |
| 52 Week High | $14.45 | $42.18 |
| Indicator | VIR | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 50.27 | 66.16 |
| Support Level | $5.55 | $37.29 |
| Resistance Level | $6.10 | $39.76 |
| Average True Range (ATR) | 0.34 | 1.34 |
| MACD | -0.03 | -0.23 |
| Stochastic Oscillator | 42.08 | 71.85 |
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.